TABLE 2.
Dose–response relationships of candidate ototoxic drugs represented as hair cell survival after treatment with increasing doses of each drug
| Drug | Hair cell survival (% of control) | ANOVA | ||||
|---|---|---|---|---|---|---|
| 0 μM | 50 μM | 100 μM | 200 μM | 400 μM | ||
| Candesartan | 100 ± 11 | 90 ± 9 | 82 ± 9 | 67 ± 13 | Dead | p < 0.0001 |
| Chloramphenicol | 100 ± 15 | 42 ± 18 | 19 ± 7 | 19 ± 10 | 10 ± 11 | p < 0.0001 |
| Chlorophyllide | 100 ± 18 | 92 ± 7 | 47 ± 8 | 24 ± 15 | 7 ± 6 | p < 0.0001 |
| Chlortetracycline | 100 ± 15 | 101 ± 10 | 79 ± 24 | 63 ± 21 | 43 ± 16 | p < 0.0001 |
| Cisplatin | 100 ± 12 | 93 ± 12 | 94 ± 10 | 95 ± 12 | 88 ± 13 | p = 0.22 |
| Demeclocycline | 100 ± 12 | 101 ± 14 | 98 ± 13 | 92 ± 8 | 93 ± 9 | p = 0.21 |
| Estradiol valerate | 100 ± 16 | 60 ± 16 | 56 ± 14 | 46 ± 16 | Dead | p < 0.0001 |
| Ethacrynic acid | 100 ± 8 | 70 ± 17 | 52 ± 17 | 44 ± 12 | Dead | p < 0.0001 |
| Guaiazulene | 100 ± 11 | 83 ± 13 | 54 ± 9 | 52 ± 15 | Dead | p < 0.0001 |
| Kanamycin | 100 ± 17 | 98 ± 14 | 86 ± 15 | 84 ± 10 | 85 ± 6 | p < 0.05 |
| Mefloquine | 100 ± 13 | 91 ± 14 | 81 ± 19 | 76 ± 17 | Dead | p < 0.01 |
| Neomycin | 100 ± 14 | 74 ± 8 | 43 ± 9 | 18 ± 4 | 4 ± 4 | p < 0.0001 |
| Pentamidine | 100 ± 6 | 68 ± 9 | 57 ± 13 | 54 ± 11 | 36 ± 10 | p < 0.0001 |
| Pentetrazole | 100 ± 13 | 99 ± 14 | 91 ± 8 | 89 ± 9 | 92 ± 14 | p = 0.14 |
| Pomiferin | 100 ± 15 | 44 ± 18 | 45 ± 18 | 45 ± 18 | Dead | p < 0.0001 |
| Propantheline | 100 ± 12 | 68 ± 16 | 53 ± 16 | 49 ± 10 | 18 ± 8 | p < 0.0001 |
| Rosolic acid | 100 ± 12 | 83 ± 16 | 68 ± 14 | 22 ± 11 | 23 ± 9 | p < 0.0001 |
| Simvastatin | 100 ± 9 | 67 ± 13 | 48 ± 12 | Dead | Dead | P < 0.0001 |
| Spermadine | 100 ± 16 | 61 ± 10 | 7 ± 6 | 1 ± 2 | 1 ± 1 | p < 0.0001 |
| Tobramycin | 100 ± 12 | 95 ± 17 | 53 ± 15 | 49 ± 10 | 33 ± 15 | P < 0.0001 |
| Vincamine | 100 ± 12 | 69 ± 14 | 47 ± 15 | 45 ± 16 | 13 ± 8 | p < 0.0001 |
Dose dependency was evaluated with one-way ANOVA. Some drug doses were toxic to the fish and are indicated as “Dead.”